成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. Cell Cycle/DNA Damage Epigenetics
  2. Aurora Kinase
  3. MLN8054

MLN8054是高效,選擇性,有口服活性的極光激酶 (aurora A) 抑制劑,IC50 值為4 nM。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務(wù)

我們將采用定制合成服務(wù)的方式為您快速提供所需產(chǎn)品和技術(shù)服務(wù)

MLN8054 Chemical Structure

MLN8054 Chemical Structure

CAS No. : 869363-13-3

1.  客戶無需承擔(dān)相應(yīng)的運輸費用。

2.  同一機構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機構(gòu)(單位)一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
1 mg ¥454
In-stock
5 mg ¥1100
In-stock
10 mg ¥1600
In-stock
25 mg ¥3000
In-stock
50 mg ¥4800
In-stock
100 mg 現(xiàn)貨 詢價
200 mg   詢價  
500 mg   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of MLN8054:

查看 Aurora Kinase 亞型特異性產(chǎn)品:

  • 生物活性

  • 實驗參考方法

  • 純度 & 產(chǎn)品資料

  • 參考文獻

生物活性

MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC50 of 4 nM.

IC50 & Target

Aurora A

4 nM (IC50)

細胞效力
(Cellular Effect)
Cell Line Type Value Description References
Calu-6 IC50
0.22 μM
Compound: MLN-8054
Antiproliferative activity against human Calu6 cells after 96 hrs by BrdU cell proliferation ELISA
Antiproliferative activity against human Calu6 cells after 96 hrs by BrdU cell proliferation ELISA
[PMID: 17360485]
DLD-1 IC50
1.43 μM
Compound: MLN-8054
Antiproliferative activity against human DLD1 cells after 96 hrs by BrdU cell proliferation ELISA
Antiproliferative activity against human DLD1 cells after 96 hrs by BrdU cell proliferation ELISA
[PMID: 17360485]
HCT-116 IC50
0.1 μM
Compound: 1, MLN-8054
Antiproliferative activity against human HCT116 cells after 4 days by celltiter assay
Antiproliferative activity against human HCT116 cells after 4 days by celltiter assay
[PMID: 19402633]
HCT-116 IC50
0.16 μM
Compound: 1, MLN-8054
Inhibition of Aurora A in human HCT116 cells assessed as complete failure of centrosome seperation by immunofluorescence assay
Inhibition of Aurora A in human HCT116 cells assessed as complete failure of centrosome seperation by immunofluorescence assay
[PMID: 19402633]
HCT-116 IC50
0.18 μM
Compound: MLN-8054
Antiproliferative activity against human HCT116 cells after 96 hrs by BrdU cell proliferation ELISA
Antiproliferative activity against human HCT116 cells after 96 hrs by BrdU cell proliferation ELISA
[PMID: 17360485]
HCT-116 GI50
0.22 μM
Compound: 8, MLN8054
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation by BrdU incorporation assay
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation by BrdU incorporation assay
[PMID: 26101564]
HCT-116 IC50
0.31 μM
Compound: 1, MLN-8054
Inhibition of Aurora A in human HCT116 cells assessed as complete loss of phospho-Aurora A staining in centrosomes by immunofluorescence assay
Inhibition of Aurora A in human HCT116 cells assessed as complete loss of phospho-Aurora A staining in centrosomes by immunofluorescence assay
[PMID: 19402633]
HCT-116 IC50
0.69 μM
Compound: MLN8054
Cytotoxicity against human HCT116 cells after 5 days by MTS assay
Cytotoxicity against human HCT116 cells after 5 days by MTS assay
[PMID: 22326168]
HCT-116 IC50
0.85 μM
Compound: MLN8054
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 30143423]
HCT-116 IC50
34 nM
Compound: 8, MLN8054
Inhibition of aurora kinase A autophosphorylation at T288 in human HCT116 cells by immunofluorescence analysis
Inhibition of aurora kinase A autophosphorylation at T288 in human HCT116 cells by immunofluorescence analysis
[PMID: 26101564]
HCT-116 IC50
34 nM
Compound: 4, MLN-8054
Inhibition of aurora A autophosphorylation in human HCT116 cells by immunofluorescence method
Inhibition of aurora A autophosphorylation in human HCT116 cells by immunofluorescence method
[PMID: 19320489]
HCT-116 IC50
4 μM
Compound: 4, MLN-8054
Inhibition of aurora B in human HCT116 cells assessed as inhibition of histone H3 Ser10 phosphorylation by immunofluorescence method
Inhibition of aurora B in human HCT116 cells assessed as inhibition of histone H3 Ser10 phosphorylation by immunofluorescence method
[PMID: 19320489]
HCT-116 IC50
5 μM
Compound: 1, MLN-8054
Inhibition of Aurora B in human HCT116 cells assessed as complete loss of phospho-histamine H3 staining by immunofluorescence assay
Inhibition of Aurora B in human HCT116 cells assessed as complete loss of phospho-histamine H3 staining by immunofluorescence assay
[PMID: 19402633]
HCT-116 IC50
5.2 μM
Compound: 8, MLN8054
Inhibition of aurora kinase B in human HCT116 cells assessed as inhibition of histone H3 phosphorylation by immunofluorescence analysis
Inhibition of aurora kinase B in human HCT116 cells assessed as inhibition of histone H3 phosphorylation by immunofluorescence analysis
[PMID: 26101564]
HeLa IC50
0.034 μM
Compound: MLN-8054
Inhibition of Aurora A Thr288 autophosphorylation in human HeLa cells after 1 hr
Inhibition of Aurora A Thr288 autophosphorylation in human HeLa cells after 1 hr
[PMID: 17360485]
HeLa IC50
5.7 μM
Compound: MLN-8054
Inhibition of Aurora B Ser10 phosphorylation in human HeLa cells after 1 hr
Inhibition of Aurora B Ser10 phosphorylation in human HeLa cells after 1 hr
[PMID: 17360485]
HT-29 IC50
0.15 μM
Compound: 1, MLN-8054
Antiproliferative activity against human HT-29 cells after 4 days by celltiter assay
Antiproliferative activity against human HT-29 cells after 4 days by celltiter assay
[PMID: 19402633]
MCF7 IC50
0.67 μM
Compound: MLN-8054
Antiproliferative activity against human MCF7 cells after 96 hrs by BrdU cell proliferation ELISA
Antiproliferative activity against human MCF7 cells after 96 hrs by BrdU cell proliferation ELISA
[PMID: 17360485]
MDA-MB-231 IC50
0.74 μM
Compound: MLN-8054
Antiproliferative activity against human MDAMB231 cells after 96 hrs by BrdU cell proliferation ELISA
Antiproliferative activity against human MDAMB231 cells after 96 hrs by BrdU cell proliferation ELISA
[PMID: 17360485]
NCI-H460 IC50
0.11 μM
Compound: MLN-8054
Antiproliferative activity against human H460 cells after 96 hrs by BrdU cell proliferation ELISA
Antiproliferative activity against human H460 cells after 96 hrs by BrdU cell proliferation ELISA
[PMID: 17360485]
PC-3 IC50
0.79 μM
Compound: MLN-8054
Antiproliferative activity against human PC3 cells after 96 hrs by BrdU cell proliferation ELISA
Antiproliferative activity against human PC3 cells after 96 hrs by BrdU cell proliferation ELISA
[PMID: 17360485]
Sf9 IC50
0.004 μM
Compound: MLN-8054
Inhibition of mouse recombinant Aurora A kinase expressed in insect Sf9 cells by radioactive flashplate assay
Inhibition of mouse recombinant Aurora A kinase expressed in insect Sf9 cells by radioactive flashplate assay
[PMID: 17360485]
Sf9 IC50
0.172 μM
Compound: MLN-8054
Inhibition of mouse recombinant Aurora B kinase expressed in insect Sf9 cells by radioactive flashplate assay
Inhibition of mouse recombinant Aurora B kinase expressed in insect Sf9 cells by radioactive flashplate assay
[PMID: 17360485]
Sf9 IC50
172 nM
Compound: MLN8054
Inhibition of GST-tagged recombinant mouse Aurora B expressed in Sf9 cells using Biotin-TKQTARKSTGGKAPR as peptide substrate by [gamma-33S]ATP binding assay
Inhibition of GST-tagged recombinant mouse Aurora B expressed in Sf9 cells using Biotin-TKQTARKSTGGKAPR as peptide substrate by [gamma-33S]ATP binding assay
[PMID: 24681066]
Sf9 IC50
172 nM
Compound: MLN8054
Inhibition of mouse recombinant Aurora B expressed in Sf9 cells using Biotin-TKQTARKSTGGKAPR as substrate and [gamma33P]ATP by flashplate assay
Inhibition of mouse recombinant Aurora B expressed in Sf9 cells using Biotin-TKQTARKSTGGKAPR as substrate and [gamma33P]ATP by flashplate assay
[PMID: 22803810]
Sf9 IC50
31 nM
Compound: 8, MLN8054
Inhibition of recombinant mouse aurora kinase A expressed in insect Sf9 cells using biotin-GLRRASLG as substrate in presence of [gamma-33P]ATP
Inhibition of recombinant mouse aurora kinase A expressed in insect Sf9 cells using biotin-GLRRASLG as substrate in presence of [gamma-33P]ATP
[PMID: 26101564]
Sf9 IC50
4 nM
Compound: MLN8054
Inhibition of recombinant mouse Aurora A kinase expressed in Sf9 cells using Biotin-GLRRASLG as substrate in presence of [gamma33]P-ATP by FlashPlate assay
Inhibition of recombinant mouse Aurora A kinase expressed in Sf9 cells using Biotin-GLRRASLG as substrate in presence of [gamma33]P-ATP by FlashPlate assay
[PMID: 30502115]
Sf9 IC50
4 nM
Compound: MLN8054
Inhibition of GST-tagged recombinant mouse Aurora A expressed in Sf9 cells using biotin-GLRRASLG as peptide substrate by [gamma-33S]ATP binding assay
Inhibition of GST-tagged recombinant mouse Aurora A expressed in Sf9 cells using biotin-GLRRASLG as peptide substrate by [gamma-33S]ATP binding assay
[PMID: 24681066]
Sf9 IC50
4 nM
Compound: MLN8054
Inhibition of mouse recombinant Aurora A expressed in Sf9 cells using Biotin-GLRRASLG as substrate and [gamma33P]ATP by flashplate assay
Inhibition of mouse recombinant Aurora A expressed in Sf9 cells using Biotin-GLRRASLG as substrate and [gamma33P]ATP by flashplate assay
[PMID: 22803810]
SK-OV-3 IC50
0.53 μM
Compound: MLN-8054
Antiproliferative activity against human SKOV3 cells after 96 hrs by BrdU cell proliferation ELISA
Antiproliferative activity against human SKOV3 cells after 96 hrs by BrdU cell proliferation ELISA
[PMID: 17360485]
SW480 IC50
0.86 μM
Compound: MLN-8054
Antiproliferative activity against human SW480 cells after 96 hrs by BrdU cell proliferation ELISA
Antiproliferative activity against human SW480 cells after 96 hrs by BrdU cell proliferation ELISA
[PMID: 17360485]
體外研究
(In Vitro)

MLN8054 is an ATP-competitive, reversible inhibitor of recombinant Aurora A kinase. MLN8054 is >40-fold more selective for Aurora A compared with the family member Aurora B. MLN8054 selectively inhibits Aurora A over Aurora B in cultured human tumor cells. MLN8054 treatment results in G2/M accumulation and spindle defects and inhibits proliferation in multiple cultured human tumor cells lines. MLN8054 effectively inhibits the growth of cells from diverse tissue origins with IC50 values ranging from 0.11 to 1.43 μM[1]. Treatment of human tumor cells grown in culture with MLN8054 shows a number of morphologic and biochemical changes associated with senescence[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

In the HCT-116 tumor-bearing mice, MLN8054 treatment inhibits tumor growth dose dependently. MLN8054 is generally well tolerated. MLN8054 also inhibits the growth of the PC-3 tumor xenograft in nude mice. MLN8054 Treatment Results in Inhibition of Aurora A, Accumulation of Mitotic Cells, and Apoptosis in vivo[1]. MLN8054 selectively inhibits Aurora A kinase activity when dosed at 30 mg/kg. At this dose in HCT116 tumor tissue, MLN8054 has been shown to inhibit Aurora A autophosphorylation, and induce an increase in the Aurora B substrate, pHisH3[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
分子量

476.86

Formula

C25H15ClF2N4O2

CAS 號
性狀

固體

顏色

White to yellow

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
溶解性數(shù)據(jù)
細胞實驗: 

DMSO 中的溶解度 : 20.83 mg/mL (43.68 mM; 超聲助溶 (<60°C); 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響,請使用新開封的 DMSO)

配制儲備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 2.0971 mL 10.4853 mL 20.9705 mL
5 mM 0.4194 mL 2.0971 mL 4.1941 mL
查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C儲存時,請在1年內(nèi)使用, -20°C儲存時,請在6個月內(nèi)使用。

  • 摩爾計算器

  • 稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動物實驗:

請根據(jù)您的 實驗動物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液,再依次添加助溶劑:
——為保證實驗結(jié)果的可靠性,澄清的儲備液可以根據(jù)儲存條件,適當(dāng)保存;體內(nèi)實驗的工作液,建議您現(xiàn)用現(xiàn)配,當(dāng)天使用;
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (5.24 mM); 懸濁液; 超聲助溶

    此方案可獲得 2.5 mg/mL的均勻懸濁液,懸濁液可用于口服和腹腔注射。

    1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

    2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。
  • 方案 二

    請依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (4.36 mM); 澄清溶液

    此方案可獲得 ≥ 2.08 mg/mL(飽和度未知)的澄清溶液。

    1 mL 工作液為例,取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
動物溶解方案計算器
請輸入動物實驗的基本信息:

給藥劑量

mg/kg

動物的平均體重

g

每只動物的給藥體積

μL

動物數(shù)量

由于實驗過程有損耗,建議您多配一只動物的量
請輸入您的動物體內(nèi)配方組成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的動物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
方案所需 助溶劑 包括:DMSO ,均可在 MCE 網(wǎng)站選購。 ,Tween 80,均可在 MCE 網(wǎng)站選購。
計算結(jié)果
工作液所需濃度 : mg/mL
儲備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
您所需的儲備液濃度超過該產(chǎn)品的實測溶解度,以下方案僅供參考,如有需要,請與 MCE 中國技術(shù)支持聯(lián)系。
動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液,加入 μL 。 μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水。
連續(xù)給藥周期超過半月以上,請謹慎選擇該方案。
請確保第一步儲備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.54%

參考文獻
Cell Assay
[1]

MLN8054 is added to human tumor cells in 2-fold serial dilutions to achieve final concentrations ranging from 10 to 0.04 mM. MLN8054 at each dilution is added in triplicate with each replicate on a separate plate. Cells treated with DMSO (n=6 wells per plate; 0.2% final concentration) served as the untreated control. The cells are treated with MLN8054 for 96 h at 37°C in a humidified cell culture chamber. Cell viability in each cell line is measured by using the Cell Proliferation ELISA, BrdU colorimetric kit[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Mice: Nude mice bearing HCT-116 tumors are treated orally once per day for 21 consecutive days with either vehicle control or MLN8054 at doses of 3, 10, or 30 mg/kg. Tumor volumes are measured by using a vernier caliper and calculated[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻

完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復(fù)凍融造成的產(chǎn)品失效
儲備液的保存方式和期限:-80°C, 1 year; -20°C, 6 months。-80°C儲存時,請在1年內(nèi)使用, -20°C儲存時,請在6個月內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.0971 mL 10.4853 mL 20.9705 mL 52.4263 mL
5 mM 0.4194 mL 2.0971 mL 4.1941 mL 10.4853 mL
10 mM 0.2097 mL 1.0485 mL 2.0971 mL 5.2426 mL
15 mM 0.1398 mL 0.6990 mL 1.3980 mL 3.4951 mL
20 mM 0.1049 mL 0.5243 mL 1.0485 mL 2.6213 mL
25 mM 0.0839 mL 0.4194 mL 0.8388 mL 2.0971 mL
30 mM 0.0699 mL 0.3495 mL 0.6990 mL 1.7475 mL
40 mM 0.0524 mL 0.2621 mL 0.5243 mL 1.3107 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱:

 

* 需求量:

* 客戶姓名:

 

* Email:

* 電話:

 

* 公司或機構(gòu)名稱:

   留言給我們:

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱:
MLN8054
目錄號:
HY-10180
需求量: